Interactions between the gut microbiome and immune system influence cancer immune surveillance, though the mechanism through which these gut-primed immune cells regulate peripheral antitumor immune response is not well understood. Now, two recent studies in Science and Science Immunology using mouse models and human tissue samples have highlighted a group of intestinal T cells with the gut-homing α4β7 integrin receptors that play a critical role in mediating response to immune checkpoint blockade cancer immunotherapy. Read More

Part of the reason for CAR T cells’ astonishing success in B-cell cancers is that B cells are astonishingly easy to replace. CAR T cells are specific, yes. But they are not specific to tumor cells. They are specific to their target antigens. In the case of Yescarta (axicabtagene ciloleucel, Gilead Sciences Inc.) and Kymriah (tisagenlecleucel, Novartis AG), the first two clinically approved T cells, that target is CD19, which is expressed on B-cell precursors. And when it is successful, the treatment leaves patients without any B cells at all. Read More

Cancervax Inc. has announced further progress made by its research team at the University of California, Los Angeles (UCLA) toward... Read More

Recent studies have demonstrated that WNT/β-catenin signaling is essential for the regulation of both blood-brain barrier (BBB) and blood... Read More

The most frequently mutated oncogenic driver mutation, KRAS, is associated with several types of cancer such as pancreatic, lung or colorectal... Read More

Neobiosis LLC has received FDA clearance of its IND application for Vixome for the treatment of post-COVID syndrome, or long-haul COVID... Read More

Hepaitech (Beijing) Biopharma Technology Co. Ltd. has disclosed bile acids acting as farnesoid X receptor (FXR) and/or G-protein coupled bile... Read More

Researchers at Jinan University (Guangdong) and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have synthesized... Read More

Lantern Pharma Inc. has received IND clearance from the FDA for LP-184, which is being developed for advanced solid tumors and central nervous system (CNS) cancers. Read More

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bruton tyrosine kinase (BTK) targeting moiety via linker and thus acting as BTK degradation inducers. Read More

Chengdu Baiyu Pharmaceutical Co Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors with improved blood-brain barrier penetration ability and reported to be useful for the treatment of cancer. Read More

CSPC Pharmaceutical Group Ltd. has received clinical trial clearance by China’s National Medical Products Administration (NMPA) for SYH-2051 for solid tumors. Read More

Elgen Therapeutics Inc. has described histone-lysine N-methyltransferase 2A (KMT2A, MLL1) inhibitors reported to be useful for the treatment of cancer. Read More

Tetra Pharm Technologies Aps has announced promising results from preclinical testing of its pain-relieving drug, TPT-0301, which targets the endocannabinoid system. Read More

Chemokine (C-C motif) receptor 8 (CCR8), a member of the β chemokine receptor family, contributes to the recruitment and immunosuppressive function of regulatory T (Treg) cells within the tumor microenvironment. Read More

At the recent EAACI meeting, researchers presented preclinical data for the inflammasome inhibitor OLT-1177 (dapansutrile), which is being evaluated by Olatec Therapeutics LLC for the treatment of inflammatory diseases. Read More